News

TipRanks on MSN6d

AbbVie’s Phase 3 Study on Upadacitinib for Alopecia Areata: Market Implications

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...
TipRanks on MSN4d

AbbVie’s Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa: A Potential Game Changer

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...
PMLive6d

AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

AbbVie has shared promising top-line results from a late-stage study of its JAK inhibitor Rinvoq (upadacitinib) in severe ...

Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentation. Current pipeline developments reflect a move ...
pharmaphorum4d

AbbVie breaks new ground for IL-23 drug Skyrizi in IBD

AbbVie’s Skyrizi is approved by the FDA for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease.